These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Potential diagnostic value of CSF metabolism-related proteins across the Alzheimer's disease continuum. Paciotti S; Wojdała AL; Bellomo G; Toja A; Chipi E; Piersma SR; Pham TV; Gaetani L; Jimenez CR; Parnetti L; Chiasserini D Alzheimers Res Ther; 2023 Jul; 15(1):124. PubMed ID: 37454217 [TBL] [Abstract][Full Text] [Related]
6. Integrated analysis of ultra-deep proteomes in cortex, cerebrospinal fluid and serum reveals a mitochondrial signature in Alzheimer's disease. Wang H; Dey KK; Chen PC; Li Y; Niu M; Cho JH; Wang X; Bai B; Jiao Y; Chepyala SR; Haroutunian V; Zhang B; Beach TG; Peng J Mol Neurodegener; 2020 Jul; 15(1):43. PubMed ID: 32711556 [TBL] [Abstract][Full Text] [Related]
7. Cerebrospinal fluid proteomics and biological heterogeneity in Alzheimer's disease: A literature review. Wesenhagen KEJ; Teunissen CE; Visser PJ; Tijms BM Crit Rev Clin Lab Sci; 2020 Mar; 57(2):86-98. PubMed ID: 31694431 [TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort. Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385 [TBL] [Abstract][Full Text] [Related]
9. Cognitive impairment in late-life bipolar disorder is not associated with Alzheimer's disease pathological signature in the cerebrospinal fluid. Forlenza OV; Aprahamian I; Radanovic M; Talib LL; Camargo MZ; Stella F; Machado-Vieira R; Gattaz WF Bipolar Disord; 2016 Feb; 18(1):63-70. PubMed ID: 26876913 [TBL] [Abstract][Full Text] [Related]
10. Proteomic Profiling of Extracellular Vesicles Derived from Cerebrospinal Fluid of Alzheimer's Disease Patients: A Pilot Study. Muraoka S; Jedrychowski MP; Yanamandra K; Ikezu S; Gygi SP; Ikezu T Cells; 2020 Aug; 9(9):. PubMed ID: 32854315 [TBL] [Abstract][Full Text] [Related]
11. Association of Cerebrospinal Fluid S100B Protein with Core Biomarkers and Cognitive Deficits in Prodromal and Mild Alzheimer's Disease. Christl J; Verhülsdonk S; Pessanha F; Menge T; Seitz RJ; Kujovic M; Höft B; Supprian T; Lange-Asschenfeldt C J Alzheimers Dis; 2019; 72(4):1119-1127. PubMed ID: 31683478 [TBL] [Abstract][Full Text] [Related]
12. Plasma neuregulin 1 as a synaptic biomarker in Alzheimer's disease: a discovery cohort study. Vrillon A; Mouton-Liger F; Martinet M; Cognat E; Hourregue C; Dumurgier J; Bouaziz-Amar E; Brinkmalm A; Blennow K; Zetterberg H; Hugon J; Paquet C Alzheimers Res Ther; 2022 May; 14(1):71. PubMed ID: 35606871 [TBL] [Abstract][Full Text] [Related]
13. Extracellular vesicle proteome unveils cathepsin B connection to Alzheimer's disease pathogenesis. Yuyama K; Sun H; Fujii R; Hemmi I; Ueda K; Igeta Y Brain; 2024 Feb; 147(2):627-636. PubMed ID: 38071653 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of visinin-like protein 1 concentrations in the cerebrospinal fluid of patients with mild cognitive impairment as a dynamic biomarker of Alzheimer's disease. Mroczko B; Groblewska M; Zboch M; Muszyński P; Zajkowska A; Borawska R; Szmitkowski M; Kornhuber J; Lewczuk P J Alzheimers Dis; 2015; 43(3):1031-7. PubMed ID: 25159667 [TBL] [Abstract][Full Text] [Related]
15. Identification of SPARC-like 1 protein as part of a biomarker panel for Alzheimer's disease in cerebrospinal fluid. Vafadar-Isfahani B; Ball G; Coveney C; Lemetre C; Boocock D; Minthon L; Hansson O; Miles AK; Janciauskiene SM; Warden D; Smith AD; Wilcock G; Kalsheker N; Rees R; Matharoo-Ball B; Morgan K J Alzheimers Dis; 2012; 28(3):625-36. PubMed ID: 22045497 [TBL] [Abstract][Full Text] [Related]
17. Performance Evaluation of an Automated ELISA System for Alzheimer's Disease Detection in Clinical Routine. Chiasserini D; Biscetti L; Farotti L; Eusebi P; Salvadori N; Lisetti V; Baschieri F; Chipi E; Frattini G; Stoops E; Vanderstichele H; Calabresi P; Parnetti L J Alzheimers Dis; 2016 Jul; 54(1):55-67. PubMed ID: 27447425 [TBL] [Abstract][Full Text] [Related]
18. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study. Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097 [TBL] [Abstract][Full Text] [Related]
19. Interactions between amyloid-β and tau in cerebrospinal fluid of people with mild cognitive impairment and Alzheimer's disease. Kristofikova Z; Ricny J; Kolarova M; Vyhnalek M; Hort J; Laczo J; Sirova J; Ripova D J Alzheimers Dis; 2014; 42 Suppl 3():S91-8. PubMed ID: 24670397 [TBL] [Abstract][Full Text] [Related]
20. Different Inflammatory Signatures in Alzheimer's Disease and Frontotemporal Dementia Cerebrospinal Fluid. Boström G; Freyhult E; Virhammar J; Alcolea D; Tumani H; Otto M; Brundin RM; Kilander L; Löwenmark M; Giedraitis V; Lleó A; von Arnim CAF; Kultima K; Ingelsson M J Alzheimers Dis; 2021; 81(2):629-640. PubMed ID: 33814444 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]